Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study
- PMID: 19480469
- DOI: 10.2165/00023210-200923060-00005
Aripiprazole monotherapy in children and young adolescents with pervasive developmental disorders: a retrospective study
Abstract
Background: Pervasive developmental disorders (PDDs) are severe psychiatric disorders characterized by impairment in social interactions, in verbal and non-verbal communication, and by restricted and stereotyped patterns of interest and behaviour, with onset in the first 3 years of life. The appropriate use of pharmacotherapy can improve some aberrant symptoms and behaviours and increase the person's response to non-pharmacological interventions.
Objective: To describe clinical outcomes, or symptom changes, and adverse effects during naturalistic treatment with aripiprazole monotherapy in children with PDDs and severe behavioural disorders (such as aggression against self and/or others, hostility, hyperactivity, severe impulsiveness).
Method: This retrospective naturalistic study included 34 patients (23 males and 11 females, age range 4.5-15 years, mean age 10.2 +/- 3.3 years), admitted during 2006-2007, diagnosed according to DSM-IV criteria and followed up for 4-12 months (mean 7.0 +/- 3.6 months). Outcome measures were three global measures of clinical and functional impairment and improvement from baseline: the Clinical Global Impression-Severity (CGI-S) and CGI-Improvement (CGI-I) scales; the Children's Global Assessment Scale (C-GAS); and the Childhood Autism Rating Scale (CARS), a specific measure of PDD symptoms.
Results: The mean baseline CGI-S was 5.7 +/- 0.8 (markedly ill/severely ill). The mean final dosage of aripiprazole was 8.1 +/- 4.9 mg/day. At the endpoint, 11 patients (32.4%) were 'much improved' or 'very much improved' (CGI-I score of 1 or 2), 12 patients (35.3%) were 'minimally improved' (CGI-I score of 3) and 10 (29.4%) were 'unchanged' or 'worsened' (CGI-I score of 4 or 5). C-GAS and CARS scores significantly improved (p < 0.0001, effect sizes 0.59 and 0.62, respectively). Nine patients (26.5%) experienced moderate to severe agitation, which was associated with self-injurious behaviours in five of these patients, and five patients presented with sleep disorders. Twelve patients (35.3%) discontinued medication during the follow-up because of lack of efficacy or adverse effects.
Conclusions: In these severely impaired children with PDDs, aripiprazole monotherapy was associated with a significant improvement in maladaptive behaviours in one-third of patients. Agitation and insomnia were the most frequent adverse effects. Further controlled studies in larger samples to explore possible predictors of efficacy are warranted.
Similar articles
-
Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.J Child Adolesc Psychopharmacol. 2009 Jun;19(3):265-74. doi: 10.1089/cap.2008.093. J Child Adolesc Psychopharmacol. 2009. PMID: 19519261 Free PMC article. Clinical Trial.
-
Aripiprazole augmentation in 39 adolescents with medication-resistant obsessive-compulsive disorder.J Clin Psychopharmacol. 2010 Dec;30(6):688-93. doi: 10.1097/jcp.0b013e3181fab7b1. J Clin Psychopharmacol. 2010. PMID: 21105283 Clinical Trial.
-
Effectiveness of lithium in children and adolescents with conduct disorder: a retrospective naturalistic study.CNS Drugs. 2009;23(1):59-69. doi: 10.2165/0023210-200923010-00004. CNS Drugs. 2009. PMID: 19062775 Clinical Trial.
-
Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders.J Clin Psychiatry. 2008;69 Suppl 4:15-20. J Clin Psychiatry. 2008. PMID: 18533764 Review.
-
Aripiprazole in autism spectrum disorders and fragile X syndrome.Neurotherapeutics. 2010 Jul;7(3):258-63. doi: 10.1016/j.nurt.2010.04.001. Neurotherapeutics. 2010. PMID: 20643378 Free PMC article. Review.
Cited by
-
A randomised controlled trial of bumetanide in the treatment of autism in children.Transl Psychiatry. 2012 Dec 11;2(12):e202. doi: 10.1038/tp.2012.124. Transl Psychiatry. 2012. PMID: 23233021 Free PMC article. Clinical Trial.
-
Effects of risperidone on core symptoms of autistic disorder based on childhood autism rating scale: an open label study.Indian J Psychol Med. 2014 Jan;36(1):66-70. doi: 10.4103/0253-7176.127254. Indian J Psychol Med. 2014. PMID: 24701014 Free PMC article.
-
Effects of repeated and acute aripiprazole or haloperidol treatment on dopamine synthesis in the dorsal striatum of young rats: comparison to adult rats.J Neural Transm (Vienna). 2010 May;117(5):573-83. doi: 10.1007/s00702-010-0396-5. Epub 2010 Apr 6. J Neural Transm (Vienna). 2010. PMID: 20372943
-
Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.Transl Psychiatry. 2017 Mar 14;7(3):e1056. doi: 10.1038/tp.2017.10. Transl Psychiatry. 2017. PMID: 28291262 Free PMC article. Clinical Trial.
-
Aripiprazole for autism spectrum disorders (ASD).Cochrane Database Syst Rev. 2016 Jun 26;2016(6):CD009043. doi: 10.1002/14651858.CD009043.pub3. Cochrane Database Syst Rev. 2016. PMID: 27344135 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources